Plain-English translation of NCT07319676 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new type of immunotherapy called CAR T-cell therapy, which uses your own immune cells that are genetically modified in the laboratory to recognize and fight your cancer. The therapy targets proteins called CD19 and/or CD22 that appear on the surface of certain blood cancer cells. This treatment is being studied in patients whose cancer has come back or is no longer responding to standard chemotherapy.
Many patients with advanced blood cancers run out of effective treatment options after standard chemotherapy or transplant. This medication is designed to work differently—by training your own immune system to attack cancer cells directly—offering hope for patients who have limited choices left.
You likely qualify if…
You likely don't qualify if…
First, doctors will take a sample of your blood and examine your cancer cells in detail to determine the best targets. Your blood cells will then be sent to a laboratory where they are genetically modified over several weeks to recognize and attack your cancer. Once ready, you will receive an infusion of these modified cells back into your body. You will need to stay in or near Singapore for at least 3 months after the infusion for close monitoring, with follow-up visits and scans to track how well the treatment is working.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Singapore